Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.
AstraZeneca, Lilly, Novo Nordisk, and Sanofi filed their latest brief on Feb. 4 in New York state health center Mosaic Health and Virginia-based Central Virginia Health Services’ (CVHS) antitrust suit. U.S. Chief District Judge Elizabeth Wolford of U.S. District Court for the District of Western New York is hearing the case.
Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
